The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Therapeutic effect of TAS-102 (A) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy by the Köhne model (Km).
Tomohiro Nishina
Honoraria - Taiho Pharmaceutical
Takayuki Yoshino
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Other Remuneration - Taiho Pharmaceutical
Nobuyuki Mizunuma
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Kentaro Yamazaki
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Yoshito Komatsu
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Hideo Baba
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Other Remuneration - Taiho Pharmaceutical
Akihito Tsuji
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Other Remuneration - Taiho Pharmaceutical
Kensei Yamaguchi
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Kei Muro
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Atsushi Ohtsu
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Other Remuneration - Taiho Pharmaceutical